NuCana (NCNA) Common Equity (2016 - 2025)
NuCana's (NCNA) quarterly Common Equity came in at $32.4 million in Q4 2025, up 323.44% year-on-year from $7.6 million in Q4 2024, and down 7.5% quarter-over-quarter from $35.0 million in Q3 2025.
NuCana (NCNA) Common Equity (2016 - 2025) Analysis & Trends
NuCana has disclosed Common Equity across 10 years of filings, most recently posting $32.4 million for Q4 2025.
- Common Equity for Q4 2025 came in at $32.4 million, up 323.44% year-over-year; the trailing twelve-month figure through Dec 2025 was $32.4 million (up 323.44% YoY), and the FY2025 annual result was $32.1 million, up 321.44% from the prior year.
- Common Equity came in at $32.4 million for Q4 2025 at NuCana, down from $35.0 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $126.1 million in Q1 2021 to a low of $4.8 million in Q2 2024.
- The 5-year median for Common Equity is $34.6 million (2023), against an average of $46.4 million.
- Across the five-year window, Common Equity slumped 86.0% in 2024 and soared 519.25% in 2025, its largest moves.
- NuCana's Common Equity stood at $88.4 million in 2021, then plunged by 48.89% to $45.2 million in 2022, then tumbled by 59.09% to $18.5 million in 2023, then slumped by 58.64% to $7.6 million in 2024, then soared by 323.44% to $32.4 million in 2025.
- The last three Common Equity figures came in at $32.4 million (Q4 2025), $35.0 million (Q3 2025), and $9.9 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | 35.63 Mn |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | -1.42 Mn |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | 14.38 Mn |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | 13.21 Mn |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | 11.87 Mn |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 19.36 Bn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | - |
| 10 | NuCana | 29.13 Bn | 29.13 Bn | - | 32.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 32.36 Mn |
| Sep 30, 2025 | 34.98 Mn |
| Jun 30, 2025 | 9.85 Mn |
| Mar 31, 2025 | 5.26 Mn |
| Dec 31, 2024 | 7.64 Mn |
| Sep 30, 2024 | 5.65 Mn |
| Jun 30, 2024 | 4.80 Mn |
| Mar 31, 2024 | 12.85 Mn |
| Dec 31, 2023 | 18.48 Mn |
| Sep 30, 2023 | 27.58 Mn |
| Jun 30, 2023 | 34.26 Mn |
| Mar 31, 2023 | 38.59 Mn |
| Dec 31, 2022 | 45.16 Mn |
| Sep 30, 2022 | 62.10 Mn |
| Jun 30, 2022 | 70.57 Mn |
| Mar 31, 2022 | 78.79 Mn |
| Dec 31, 2021 | 88.36 Mn |
| Sep 30, 2021 | 106.77 Mn |
| Jun 30, 2021 | 117.68 Mn |
| Mar 31, 2021 | 126.11 Mn |